Executive Stock Sales
SOPHiA Genetics Executives Sell Shares Under Pre-Arranged Trading Plans
Anonymous
Key Points
1
SOPHiA GENETICS’ insider activity over the previous year was heavily weighted toward sales: 94 insider sells versus just one insider buy, while Daan Van Well had sold 20,574 shares and made no purchases during that period.
2
Van Well’s September 11 sale was executed through multiple trades ranging from $7.55 to $7.85 per share, rather than at a single price.
3
The September 11 transaction occurred as SOPHiA GENETICS shares were valued at roughly $669.1 million in market capitalization; GuruFocus estimated the stock’s intrinsic GF Value at $5.15 versus the reported trading price of $7.63, labeling it significantly overvalued by that measure.
4
The company’s latest reported quarter showed a net loss of $0.26 per share on revenue of $23.31 million; the loss missed the consensus estimate of $0.21 per share, although revenue exceeded the $21.72 million estimate.
SOPHiA GENETICS insiders sold 14,668 shares in mid-September 2026 under pre-arranged trading plans. Executive Chairman Jurgi Camblong offloaded 8,500 shares on September 10 at roughly $7.66 each, while Chief Legal Officer Daan Van Well sold 6,168 shares on September 11 at about $7.63 each, according to Kalkinemedia.
The sales continue a lopsided pattern of insider activity: 94 insiders sold shares over the past year versus just one buyer. GuruFocus estimated the stock was overvalued at $7.63, with an intrinsic value of just $5.15, while the company posted a net loss of $0.26 per share last quarter despite beating revenue estimates.
Camblong and Van Well Lead Exodus of Stock Sales
Camblong, the Executive Chairman, sold 8,500 shares on September 10 at a weighted average of $7.66 per share under a Rule 10b5-1 trading plan. After the sale, he retained 3,435,822 shares. Van Well's September 11 transaction was more fragmented — he sold 6,168 shares through multiple trades ranging from $7.55 to $7.85 per share, according to Kalkinemedia.
Van Well, the Chief Legal Officer, left with 338,884 shares following his sale. Neither executive's filing explained why they sold or whether they planned further transactions. Both used pre-arranged trading plans, which allow insiders to set up automated sales in advance to avoid appearance of trading on confidential information.
Year of Heavy Insider Selling Shows No Signs of Slowing
The pattern of insider sales at SOPHiA GENETICS has been relentless. Over the past year, 94 insiders sold shares compared to just one insider who bought. Van Well personally sold 20,574 shares during that stretch and made zero purchases, according to Kalkinemedia. The lopsided activity often signals executive concern about future stock performance.
September saw multiple other executives join the selling spree. Chief Scientific Officer Xu Zhenyu sold 4,000 shares at $7.88 on September 14. Chief Medical Officer Philippe Menu also sold 5,000 shares at $7.88 on the same day, GuruFocus reported. These transactions involved roughly 0.7% of Zhenyu's holdings and left Menu with 208,387 shares.
Valuation Gap Raises Questions About Stock Price
On September 11, SOPHiA GENETICS had a market cap of roughly $669.1 million with shares trading at $7.63. However, GuruFocus valued the company's intrinsic GF Value at just $5.15 per share — suggesting the stock was significantly overvalued by that measure. The 48% gap between trading price and estimated fair value may explain why insiders continue to lighten their holdings.
The company's most recent quarter added to concerns. SOPHiA GENETICS posted a net loss of $0.26 per share, missing the consensus estimate of $0.21. Revenue came in at $23.31 million and beat expectations of $21.72 million, yet the earnings miss and continued losses paint a picture of an unprofitable company trading at a premium valuation.
Sentiment
Mostly NegativeNEGATIVENEUTRALPOSITIVE
Publishers
16
Articles
7
Reach
23
A
AnonymousAuthor
